

Investor presentation

Q3 2019/20 results

Ambu^{*}

The world's most innovative single-use endoscopy player

Business update Financial results and outlook Q&A

Disclaimer

Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu's control, may cause the actual development of the company to differ materially from the expectations contained in this presentation. Factors that might affect such expectations include, among others, changes in healthcare, in the world economy and in exchange rates

Uniquely positioned for value creation

Competitive advantages



Global leader in single-use Visualization with 10 years of experience



Competitive advantage in **modular innovation engine** and high scale low-cost manufacturing



Commercial organization with a 100% focus on market creation and penetration of singleuse Visualization products Ambu^{*}

Unique market opportunity

\$2.5B+

single-use market opportunity by 2024



Key messages



1

The COVID-19 pandemic has accelerated the development of the single-use endoscopy market

- Healthcare systems have increased their focus on infection control and the medical community is actively evaluating contamination levels and see single-use endoscopy as an attractive solution
- The aScope[™] 4 Broncho has been used in COVID-19 patients driving an expansion of our customer base

2 21% organic revenue growth in Q3 19/20 driven by Visualization sales of +81%


- Visualization sales in Europe and Asia Pacific has more than doubled over last year
- Postponement of elective procedures drove a -15% decline in our Core business. We see gradual market improvement across geographies throughout Q3 and into July 2020
- Full-year guidance for organic revenue growth is reduced to ~26% with an EBIT% at ~12% to reflect the impact of COVID-19 in our Core business. Visualization volume target of +1m endoscope units sold remains unchanged

3 Ambu emerges from COVID-19 pandemic as a stronger company

- Today, Ambu is one of the fastest growing medical device companies. We are strengthening our organization across key capabilities from innovation to commercial infrastructure
- Positive market feedback on aView[™] 2 Advance and aScope[™] 4 Cysto
- aScope[™] Duodeno was granted designation as a breakthrough device and has received FDA clearance

1 The case for single-use endoscopy continues to strengthen





17 papers on duodenoscope contamination were presented at DDW in 2019



UPDATED GUIDELINES FROM FDA AND NATIONAL ASSOCIATIONS

2nd FDA safety communication recommending transition to duodenoscopes with innovative designs, highlighting **aScope™ Duodeno** as part of the solution


National bronchoscopy associations recommending single-use bronchoscopes in COVID-19 environment

2 COVID-19 impact on Visualization has been positive, especially in Europe

Positive impact in Visualization

- aScope[™] 4 Broncho is an important part of COVID-19 treatment in Europe and RoW with sales increasing +195% and +105% respectively
- We have seen high double-digit growth in all major European territories, with the United Kingdom as the main growth-driver in preparation for a second wave
- In the U.S., Visualization is gradually improving over Q3 and into July as health care systems restart their activities
- Expansion of manufacturing capacity for aScope™ 4 Broncho in Penang

Endoscope units sold ('000)




Amhu^{*}

2 COVID-19 impact on Core business has been negative, especially in PMD

Negative impact in Core

- Postponement of elective procedures had significant negative impact in especially PMD
- Strong demand for resuscitators to treat COVID-19 patients. Expansion of manufacturing capacity for resuscitators out of Xiamen completed
- Improved ability to deliver Anaesthesia products in RoW on the back of the surge in demand in Q2
- Gradual market improvement across geographies, and Core business back in growth in July

Core, organic growth



Amhu^{*}

3 Advancing our innovation agenda in a COVID-19 environment Ambu^{*}

	Monitors	Product	Launch		
		aView™ 2 Advance	\checkmark	🗸 Commer	
		aBox™ Console	2H, 2020/21	Launche	
	Pulmonary	aScope™ 4 Broncho	\checkmark		
		aScope BronchoSampler™	\checkmark	Succes	
		VivaSight™	\checkmark	aView™	
Q		aScope™ 5 HD	Q4, 2020/21	aScope	
anc		aScope™ 5 for smaller patients	2021/22	accope	
∧b∧		aScope™ 5 for selected procedures	2021/22		
2 F		Video laryngoscope 2.0	2021/22	aScope	
N TM	ENT	aScope™ 4 RL Intervention	\checkmark	granteo	
aView™ 2 Advance		aScope™ 4 RL Slim	\checkmark	a break	
		ENT High-Resolution	2021/22		
	Urology	aScope™ 4 Cysto	\checkmark	Experie	
		Ureteroscope	2021/22		
		Cystoscope HD	2021/22	aScope	
	Duodenoscopy (GI)	aScope™ Duodeno	\checkmark	aScope	
aBox™ Console		aScope™ Duodeno 2	2021/22	COVID	
		Cholangioscope	2021/22	expecte	
	Colonoscopy (GI)	aScope™ Colon	2H, 2020/21		
	Gastroscopy (GI)	aScope™ Gastro	2H, 2020/21	-	

Commercially available Launches in 2019/20

Successfully introduced aView™ 2 Advance and aScope™ Cysto

aScope™ Duodeno was granted designation as a breakthrough device

Experiencing delays on aScope™ Colon and aScope™ Gastro due to COVID-19. Now expected in 2H 2020/21

3 Entering urology with the U.S. launch of aScope[™] 4 Cysto

Expect rapid uptake on the back of positive feedback

Main highlight around overall scope performance and superior image resolution driven by advanced sensor, software and newest display technology platform, aView[™] 2 Advance

~500

Product demonstrations and 213 ongoing trials

out of top 100 hospitals have converted or are in trial phase

Offers opportunity to clear COVID-19 patient backlogs with significant improvement on workflow and efficiency allowing doctors to perform more procedures with existing infrastructure



3 Entering into GI with the launch of aScope[™] Duodeno

aScope[™] Duodeno was granted breakthrough designation and secured FDA clearance. Expect rapid market conversion on the back of FDA safety communications and new TPT reimbursement payment from CMS

Our controlled market release has started on selected hospitals in the U.S. Positive feedback from physicians after product demonstrations in the U.S.



We are on track to build our 170 people GI commercial organization in the U.S to support our aScope[™] Duodeno launch. We expected it to be fully deployed by end of Q1 20/21

The planned start of our clinical study has been delayed due the COVID-19 pandemic



Financial results and outlook

1-1

1/1000

Financial results Q3 2019/20




Q3 2019/20	21% organic revenue growth	16.5% EBIT margin before special items	337 Endoscopes sold ('000 units)
Guidance	~26%	~12%	+1,000
Full year 2019/20	organic revenue	EBIT margin	Endoscopes sold
	growth	before special items	('000 units)
1	Previously 26-30%	Previously 12-14%	Unchanged

- Increased demand for single-use scopes in Europe and APAC while the U.S. experienced decline in sales
- Majority of the Core portfolio was negatively affected by postponed elective procedures
- Full-year guidance is reduced to approx. 26% organic growth with an EBIT margin at approx. 12%

Organic sales growth by geography

Ambu^{*}

Q3 2019/20 revenue and growth across regions



Financial results Q3 2019/20

Reported growth of 23% and organic growth of 21%

Ambu P&L – Q3 2019/20

DKKm	Q3 2019/20	Q3 2018/19	Change in value	Change%
Revenue	947	773	174	23%
Production costs	-334	-337	3	-1%
Gross profit	613	436	177	41%
Gross margin, %	64.7	56.4	-	-
Selling and distribution costs	-320	-190	-130	68%
Development costs	-41	-26	-15	58%
Management and administration	-96	-65	-31	48%
Total capacity costs	-457	-281	-176	63%
EBIT before special items	156	155	1	1%
EBIT margin, %	16.5	20.1	-	-

21% organic growth

Increased demand for Visualization products in certain geographies

64.7% gross margin

Negative impact in 2018/19 following the SC210-discontinuation

DKK 457m capacity costs

63% increase mostly driven by commercial expansions

16.5% EBIT margin

YTD EBIT% before special items at 14.8% _____>

Amh



Cash flow, assets and debt Q3 2019/20

Milestone payment of EUR 40m relating to clearance of duodenoscope will mature in Q1 2020/21

Ambu cash flow and balance sheet – Q3 2019/20

DKKm	Q3 2019/20	Q3 2018/19	Change in value
Cash flow and ratios			
Cash flow from operating activities	314	225	89
Cash flow from investing activities before acquisitions	-127	-77	-50
Free cash flow before acquisitions	187	148	39
Balance sheet			
Total assets	4,876	4,357	519
Interest-bearing debt (NIBD)	1,253	1,112	141
Key figures			
Net working capital	569	624	
Equity ratio	49%	51%	
NIBD/EBITDA before special items	2.2x	1.5x	

DKK 187m free cash flow

Down DKK 296m at DKK -92m for the first 9 months of 19/20. Negative free cash flow is as expected

2.2x NIBD/EBITDA

Total net interest-bearing debt DKK 1,253

DKK 569m net working capital

Equal to 17% (21%) of 12 months' revenue

2019/20 Guidance





- COVID-19 has significantly increased the demand for single-use scopes, especially in Europe
- Most Core products were negatively affected as elective procedures reduced sharply in April and May, but we see a gradual market improvement into July 2020
- Full-year guidance is reduced to approx. **26% organic growth with an EBIT margin at approx. 12%**



Q&A

Conference call

DK: +45 3544 5577 UK: +44 3333 000 804 US: +1 631 913 1422

PIN code: 70317768#

For questions, please press 01

Please limit your questions to only 3 at a time and get back into the queue if you have additional questions

Investor contact information



Share Information

Ambu A/S is listed on the stock exchange in Copenhagen under the symbol AMBU B

For further company information, please visit: www.ambu.com

Investor Relations contacts



Michael Højgaard

Executive Vice President, CFO Tel.: +45 4030 4349 Email: miho@ambu.com

Nicolai Thomsen

Investor Relations Manager Tel.: +45 2620 8047 Email: nith@ambu.com

Financial calendar

2020

11 November	Q4 2019/20
09 December	Annual General Meeting 2019/20

For full list of Investor Relations events, please visit: www.ambu.com/about/corporate-info/investors/calendar



Ambu – The single-use company